Part, Chapter, Paragraph
1 I, 2. 10. 2| e.g. natural occurring vs. manufactured nanoparticles,
2 II, 5. 3. 5| higher than that of males (46 vs 41 new cases per 100,000).
3 II, 5. 5. 3| higher mortality rate (23.0% vs. 11.2%) was mainly the result
4 II, 5. 5. 3| 214.~Palmer BA, Pankratz VS, Bostwick JM (2005): The
5 II, 5. 5. 3| was 4.9 (95% CI 2.7-8.3) vs. 7.9 (95% CI 2.6-18.4) in
6 II, 5. 5. 3| incidence of SUDEP was 2.5 vs. 6.3 per 1,000 (Nilsson
7 II, 5. 5. 3| epilepsy: driving fatalities vs other causes of death in
8 II, 5. 5. 3| Poser et al one CDMS (52% vs 38%) (Fangerau et al, 2004).~
9 II, 5. 5. 3| incident cases (symptom onset vs. date of diagnosis (Brewis
10 II, 5. 8. 6| long term care setting (41% vs. 12.5%, p<0.05) and to receive
11 II, 5. 8. 6| long-term home care (26% vs 9.7%, p<0.05), but were
12 II, 5. 8. 6| care in hospital (47.6% vs 5.1%, p<0.001) or at home (
13 II, 5. 8. 6| 0.001) or at home (37.4% vs 2.8%, p<0.05) than people
14 II, 5. 8. 7| general population. ERS vs ATS definition. Chest 2000;
15 II, 5. 9. 3| 2.20-3.12 for 1974-1979 vs 1953-1958 birth cohort).
16 II, 5. 9. 3| earlier age at onset (7.8 vs 15.9 years, P 001) and a
17 II, 5. 9. 3| duration of the disease (5.6 vs 16.1 years, P 001) than
18 II, 5. 12. 7| ligation plus propranolol vs. transjugular intrahepatic
19 II, 9 | Smoking Among all Women 25-34 vs Women During 3rd Trimester
20 II, 9. 1. 2| Smoking Among all Women 25-34 vs Women During 3rd Trimester
21 II, 9. 5. 3| Countries than EU-15 (32% vs 29%) with the highest prevalence
22 III, 10. 1. 1| subpopulations (e.g. adolescents vs adults, underserved populations
23 III, 10. 1. 1| underserved populations vs people of high socio-economic
24 III, 10. 2. 1| 40% 41% for the girls vs. 20%, 30% and 35% for the
